Procyon Corporation

PINK:PCYN USA Drug Manufacturers - Specialty & Generic
Market Cap
$1.47 Million
Market Cap Rank
#36614 Global
#11912 in USA
Share Price
$0.18
Change (1 day)
+0.00%
52-Week Range
$0.18 - $0.18
All Time High
$0.95
About

Procyon Corporation, together with its subsidiaries, manufactures and markets wound and skin care products primarily in the United States. It provides AMERIGEL, an advanced skin and wound care products, including hydrogel wound dressing, post op surgical kits, saline wound washes, and care and barrier lotions; HELIX3 Bioactive Collagen products, such as collagen powder, gel, and matrix; and calci… Read more

Procyon Corporation (PCYN) - Net Assets

Latest net assets as of September 2024: $2.29 Million USD

Based on the latest financial reports, Procyon Corporation (PCYN) has net assets worth $2.29 Million USD as of September 2024.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.20 Million) and total liabilities ($917.12K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $2.29 Million
% of Total Assets 71.38%
Annual Growth Rate 5.41%
5-Year Change -21.08%
10-Year Change 2.58%
Growth Volatility 177.16

Procyon Corporation - Net Assets Trend (1996–2025)

This chart illustrates how Procyon Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Procyon Corporation (1996–2025)

The table below shows the annual net assets of Procyon Corporation from 1996 to 2025.

Year Net Assets Change
2025-06-30 $2.33 Million +1.82%
2024-06-30 $2.29 Million -12.62%
2023-06-30 $2.62 Million -1.88%
2022-06-30 $2.67 Million -9.59%
2021-06-30 $2.95 Million +36.38%
2020-06-30 $2.16 Million +5.09%
2019-06-30 $2.06 Million +1.34%
2018-06-30 $2.03 Million -11.18%
2017-06-30 $2.29 Million +0.75%
2016-06-30 $2.27 Million +5.32%
2015-06-30 $2.16 Million -9.19%
2014-06-30 $2.37 Million +1.00%
2013-06-30 $2.35 Million -4.25%
2012-06-30 $2.45 Million +5.52%
2011-06-30 $2.33 Million +9.04%
2010-06-30 $2.13 Million +6.11%
2009-06-30 $2.01 Million +1.24%
2008-06-30 $1.99 Million +66.51%
2007-06-30 $1.19 Million +71.79%
2006-06-30 $694.23K +97.22%
2005-06-30 $352.00K +847.25%
2004-06-30 $37.16K +116.82%
2003-06-30 $-220.90K +31.75%
2002-06-30 $-323.67K -74.24%
2001-06-30 $-185.76K -137.08%
2000-06-30 $500.93K +162.62%
1999-06-30 $-800.00K -223.00%
1998-06-30 $-247.68K -151.97%
1997-06-30 $476.58K -5.58%
1996-06-30 $504.74K --

Equity Component Analysis

This analysis shows how different components contribute to Procyon Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 74857700.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock $4.47 Million 191.82%
Other Components $158.39K 6.80%
Total Equity $2.33 Million 100.00%

Procyon Corporation Competitors by Market Cap

The table below lists competitors of Procyon Corporation ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Procyon Corporation's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 2,287,290 to 2,328,885, a change of 41,595 (1.8%).
  • Net income of 33,890 contributed positively to equity growth.
  • Other comprehensive income increased equity by 114,660.
  • Other factors decreased equity by 106,955.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $33.89K +1.46%
Other Comprehensive Income $114.66K +4.92%
Other Changes $-106.95K -4.59%
Total Change $- 1.82%

Book Value vs Market Value Analysis

This analysis compares Procyon Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.65x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 1.30x to 0.65x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1996-06-30 $0.14 $0.18 x
1997-06-30 $0.13 $0.18 x
1998-06-30 $-0.06 $0.18 x
1999-06-30 $-0.15 $0.18 x
2000-06-30 $0.09 $0.18 x
2001-06-30 $-0.02 $0.18 x
2002-06-30 $-0.04 $0.18 x
2003-06-30 $-0.03 $0.18 x
2004-06-30 $0.00 $0.18 x
2005-06-30 $0.04 $0.18 x
2006-06-30 $0.08 $0.18 x
2007-06-30 $0.14 $0.18 x
2008-06-30 $0.24 $0.18 x
2009-06-30 $0.24 $0.18 x
2010-06-30 $0.26 $0.18 x
2011-06-30 $0.28 $0.18 x
2012-06-30 $0.30 $0.18 x
2013-06-30 $0.29 $0.18 x
2014-06-30 $0.29 $0.18 x
2015-06-30 $0.27 $0.18 x
2016-06-30 $0.28 $0.18 x
2017-06-30 $0.28 $0.18 x
2018-06-30 $0.25 $0.18 x
2019-06-30 $0.25 $0.18 x
2020-06-30 $0.26 $0.18 x
2021-06-30 $0.35 $0.18 x
2022-06-30 $0.33 $0.18 x
2023-06-30 $0.32 $0.18 x
2024-06-30 $0.28 $0.18 x
2025-06-30 $0.28 $0.18 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Procyon Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 1.46%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.51%
  • • Asset Turnover: 1.93x
  • • Equity Multiplier: 1.48x
  • Recent ROE (1.46%) is below the historical average (20.29%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1996 -102.90% -168.27% 0.55x 1.12x $-569.87K
1997 -146.32% -323.49% 0.37x 1.21x $-744.97K
1998 0.00% -230.46% 1.78x 0.00x $-830.69K
1999 0.00% -200.00% 1.50x 0.00x $-520.00K
2000 -63.48% -45.24% 1.15x 1.22x $-368.10K
2001 0.00% -59.88% 5.28x 0.00x $-668.11K
2002 0.00% -10.15% 5.23x 0.00x $-105.54K
2003 0.00% 1.94% 4.31x 0.00x $54.10K
2004 694.45% 12.75% 4.02x 13.55x $254.34K
2005 89.44% 14.32% 3.50x 1.79x $279.64K
2006 49.30% 14.79% 2.54x 1.31x $272.81K
2007 41.79% 19.65% 1.33x 1.60x $379.12K
2008 39.94% 30.95% 0.96x 1.35x $594.60K
2009 1.23% 1.04% 0.87x 1.35x $-176.37K
2010 5.76% 4.82% 0.89x 1.35x $-90.55K
2011 8.29% 7.14% 0.92x 1.27x $-39.72K
2012 5.23% 4.59% 0.96x 1.19x $-116.96K
2013 -4.44% -3.79% 1.03x 1.13x $-339.34K
2014 0.99% 0.83% 1.08x 1.11x $-213.79K
2015 -10.13% -7.87% 1.10x 1.17x $-433.84K
2016 4.83% 3.18% 1.11x 1.37x $-117.47K
2017 0.54% 0.31% 1.47x 1.19x $-216.37K
2018 -12.59% -6.36% 1.70x 1.16x $-458.90K
2019 1.32% 0.65% 1.72x 1.18x $-178.68K
2020 5.16% 2.58% 1.54x 1.30x $-104.71K
2021 23.53% 14.71% 1.11x 1.44x $399.25K
2022 -7.86% -4.33% 1.27x 1.43x $-476.59K
2023 -1.92% -1.07% 1.32x 1.36x $-312.02K
2024 -14.91% -6.84% 1.56x 1.40x $-569.87K
2025 1.46% 0.51% 1.93x 1.48x $-199.00K

Industry Comparison

This section compares Procyon Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $548,450,613
  • Average return on equity (ROE) among peers: -450.37%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Procyon Corporation (PCYN) $2.29 Million -102.90% 0.40x $771.70K
Ascend Wellness Holdings Inc (AAWH) $142.87 Million -33.75% 5.44x $48.90 Million
AB Science S.A (ABSCF) $10.73 Million -252.65% 3.71x $39.89 Million
Alterola Biotech Inc (ABTI) $4.85K -2005.32% 0.49x $603.58K
Aurora Cannabis Inc (ACB) $2.04 Billion -34.08% 0.34x $199.15 Million
Acreage Holdings Inc (ACRDF) $204.27 Million -30.85% 1.41x $13.48K
Acura Pharmaceuticals Inc (ACUR) $7.90 Million -63.15% 1.15x $13.20K
Agra Ventures Ltd. (AGFAF) $1.51 Million -44.22% 0.06x $298.23K
Allergy Therapeutics plc (AGYTF) $2.07 Million -2084.75% 31.32x $25.30 Million
Aida Pharmaceuticals Inc (AIDA) $6.67 Million 24.51% 2.78x $1.80
Adcock Ingram Holdings Limited (AIHLF) $3.07 Billion 20.55% 0.55x $85.61 Million